Compare FMNB & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMNB | KMDA |
|---|---|---|
| Founded | 1887 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 555.3M | 488.6M |
| IPO Year | 2010 | 2013 |
| Metric | FMNB | KMDA |
|---|---|---|
| Price | $14.09 | $8.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $14.33 | $14.00 |
| AVG Volume (30 Days) | ★ 298.0K | 52.0K |
| Earning Date | 04-24-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.80% | 2.94% |
| EPS Growth | ★ 18.85 | N/A |
| EPS | ★ 1.45 | N/A |
| Revenue | ★ $279,922,000.00 | N/A |
| Revenue This Year | $52.63 | $13.94 |
| Revenue Next Year | $8.28 | $9.84 |
| P/E Ratio | ★ $9.77 | $24.59 |
| Revenue Growth | ★ 3.89 | N/A |
| 52 Week Low | $12.23 | $6.35 |
| 52 Week High | $15.50 | $9.35 |
| Indicator | FMNB | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 67.83 | 46.58 |
| Support Level | $12.99 | $7.96 |
| Resistance Level | $14.36 | $8.50 |
| Average True Range (ATR) | 0.29 | 0.19 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 75.45 | 51.79 |
Farmers National Banc Corp is a one-bank holding company engaged in financial activities, including securities underwriting and dealing, insurance agency and underwriting activities, and merchant banking activities. It operates in the domestic banking, trust, retirement consulting, insurance, and financial management industries. The company has two operating segments of business; the Bank segment, and the Trust segment, out of which the majority of the company's revenue is derived from the bank segment.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.